Compounds > gamma-aminobutyric acid
Page last updated: 2024-10-15

gamma-aminobutyric acid and Breast Neoplasms

gamma-aminobutyric acid has been researched along with Breast Neoplasms in 57 studies

gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.

Breast Neoplasms: Tumors or cancer of the human BREAST.

Research Excerpts

ExcerptRelevanceReference
"Forty patients who were breast cancer survivors and were suffering from hot flushes to the degree that they seeked for treatment were included in the study and randomly divided into two groups: group I: (N = 20) stellate ganglion block was done for the patients of this group; and group II: (N = 20) in this group, the patients received 75 mg pregabalin twice daily."9.19Management of hot flushes in breast cancer survivors: comparison between stellate ganglion block and pregabalin. ( Othman, AH; Zaky, AH, 2014)
" This prospective randomized double-blind study was conducted to evaluate the effects of gabapentin on intraoperative propofol requirements, hemodynamic variables, and postoperative pain relief in breast cancer patients."9.17Effect of gabapentin pretreatment on propofol consumption, hemodynamic variables, and postoperative pain relief in breast cancer surgery. ( Bala, I; Bharti, N; Narayan, V; Singh, G, 2013)
"Preoperative administration of gabapentin reduced intraoperative propofol requirements and postoperative analgesic consumption in breast cancer patients undergoing total mastectomy."9.17Effect of gabapentin pretreatment on propofol consumption, hemodynamic variables, and postoperative pain relief in breast cancer surgery. ( Bala, I; Bharti, N; Narayan, V; Singh, G, 2013)
"Gabapentin is used for the treatment of hot flashes and neuropathic pain in breast cancer survivors, and is commonly used off-label for the treatment of anxiety."9.16A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors. ( Amos, E; Heckler, C; Jacobs, A; Kirshner, JJ; Lavigne, JE; Lord, R; Mathews, JL; Morrow, GR; Mustian, K; Palesh, O, 2012)
"Breast cancer survivors prefer venlafaxine over gabapentin for treating hot flashes."9.14Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. ( Bordeleau, L; Ennis, M; Goodwin, PJ; Haq, R; Jugovic, O; Loprinzi, CL; Pritchard, KI; Warr, D, 2010)
"To assess the efficacy and the tolerability of gabapentin 900 mg/day compared to vitamin E for the control of vasomotor symptoms in 115 women with breast cancer."9.14Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E. ( Biglia, N; Bounous, V; Marenco, D; Moggio, G; Peano, E; Ponzone, R; Sgandurra, P; Sismondi, P; Tomasi Cont, N, 2009)
"In this pilot study, 22 women with breast cancer on tamoxifen therapy with at least two hot flashes a day took oral gabapentin at 300 mg three times a day for 4 weeks."9.11Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer. ( Griggs, JJ; Guttuso, TJ; Morrow, GR; Pandya, KJ; Roscoe, JA; Rosenblatt, JD; Sahasrabudhe, DM; Thummala, AR, 2004)
"In an anecdotal report, complete resolution of chemotherapy-induced nausea was seen in a patient with breast cancer, after she was placed on the anticonvulsant gabapentin."9.10Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. ( Griggs, J; Guttuso, T; Roscoe, J, 2003)
" RCTs comparing gabapentin with placebo in patients undergoing breast cancer surgery were retrieved."8.98The efficacy of gabapentin in reducing pain intensity and morphine consumption after breast cancer surgery: A meta-analysis. ( Huang, Q; Jiang, Y; Li, J; Lin, H; Rong, Z; Wang, T; Xiong, J; Zhang, Q; Zhang, S, 2018)
"The purpose of this meta-analysis from randomized controlled trials (RCTs) was to determine the efficacy and safety of the preoperative use of gabapentin for the treatment of acute and chronic postoperative pain following breast cancer surgery."8.98The efficacy of gabapentin in reducing pain intensity and morphine consumption after breast cancer surgery: A meta-analysis. ( Huang, Q; Jiang, Y; Li, J; Lin, H; Rong, Z; Wang, T; Xiong, J; Zhang, Q; Zhang, S, 2018)
"Preoperative use of gabapentin was able to reduce acute and chronic postoperative pain, total morphine consumption and the occurrence of nausea following breast cancer surgery."8.98The efficacy of gabapentin in reducing pain intensity and morphine consumption after breast cancer surgery: A meta-analysis. ( Huang, Q; Jiang, Y; Li, J; Lin, H; Rong, Z; Wang, T; Xiong, J; Zhang, Q; Zhang, S, 2018)
" Meanwhile, oral gabapentin was associated with a reduction of the total morphine consumption after breast cancer surgery."8.98The efficacy of gabapentin in reducing pain intensity and morphine consumption after breast cancer surgery: A meta-analysis. ( Huang, Q; Jiang, Y; Li, J; Lin, H; Rong, Z; Wang, T; Xiong, J; Zhang, Q; Zhang, S, 2018)
" We included studies enrolling adult patients undergoing breast cancer surgery who were randomly assigned to preoperative gabapentin or pregabalin versus placebo or active control and assessed acute (≤24 h) or chronic (≥2 months) pain."8.95Preoperative pregabalin or gabapentin for acute and chronic postoperative pain among patients undergoing breast cancer surgery: A systematic review and meta-analysis of randomized controlled trials. ( Busse, JW; Choi, S; Clarke, H; Devereaux, PJ; Dhaliwal, J; Khan, JS; Rai, AS, 2017)
"Gabapentin and pregabalin administered perioperatively in patients undergoing breast cancer surgery improve acute postoperative pain as indicated by the reduction in opioid consumption."8.95Preoperative pregabalin or gabapentin for acute and chronic postoperative pain among patients undergoing breast cancer surgery: A systematic review and meta-analysis of randomized controlled trials. ( Busse, JW; Choi, S; Clarke, H; Devereaux, PJ; Dhaliwal, J; Khan, JS; Rai, AS, 2017)
"Hot flashes are a common and debilitating symptom among survivors of breast cancer."6.80Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial. ( Bowman, MA; Bruner, D; DeMichele, A; Farrar, JT; Mao, JJ; Xie, SX, 2015)
"Forty patients who were breast cancer survivors and were suffering from hot flushes to the degree that they seeked for treatment were included in the study and randomly divided into two groups: group I: (N = 20) stellate ganglion block was done for the patients of this group; and group II: (N = 20) in this group, the patients received 75 mg pregabalin twice daily."6.79Management of hot flushes in breast cancer survivors: comparison between stellate ganglion block and pregabalin. ( Othman, AH; Zaky, AH, 2014)
"Women who have survived breast cancer have hot flushes that are "significantly more frequent, severe, distressing, and of greater duration" than in other women."6.79Management of hot flushes in breast cancer survivors: comparison between stellate ganglion block and pregabalin. ( Othman, AH; Zaky, AH, 2014)
"Gabapentin is an inhibitory neurotransmitter of the central nervous system."6.78Effect of gabapentin pretreatment on propofol consumption, hemodynamic variables, and postoperative pain relief in breast cancer surgery. ( Bala, I; Bharti, N; Narayan, V; Singh, G, 2013)
"Subjects were 420 breast cancer patients who had completed all chemotherapy cycles."6.77A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors. ( Amos, E; Heckler, C; Jacobs, A; Kirshner, JJ; Lavigne, JE; Lord, R; Mathews, JL; Morrow, GR; Mustian, K; Palesh, O, 2012)
"Gabapentin was also particularly effective in improving the quality of sleep (PSQI score reduction: 21."6.74Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E. ( Biglia, N; Bounous, V; Marenco, D; Moggio, G; Peano, E; Ponzone, R; Sgandurra, P; Sismondi, P; Tomasi Cont, N, 2009)
"Gabapentin is a promising new agent in the treatment of tamoxifen induced hot flashes, and should be studied further."6.71Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer. ( Griggs, JJ; Guttuso, TJ; Morrow, GR; Pandya, KJ; Roscoe, JA; Rosenblatt, JD; Sahasrabudhe, DM; Thummala, AR, 2004)
"In this pilot study, 22 women with breast cancer on tamoxifen therapy with at least two hot flashes a day took oral gabapentin at 300 mg three times a day for 4 weeks."6.71Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer. ( Griggs, JJ; Guttuso, TJ; Morrow, GR; Pandya, KJ; Roscoe, JA; Rosenblatt, JD; Sahasrabudhe, DM; Thummala, AR, 2004)
"The secondary outcomes were incidence of chronic pain and complications (the incidence of nausea)."6.58The efficacy of gabapentin in reducing pain intensity and morphine consumption after breast cancer surgery: A meta-analysis. ( Huang, Q; Jiang, Y; Li, J; Lin, H; Rong, Z; Wang, T; Xiong, J; Zhang, Q; Zhang, S, 2018)
"Gabapentin is an anticonvulsant that the United States Food and Drug Administration approved as an adjunct therapy for partial seizures and postherpetic neuralgia."6.45Use of gabapentin in patients experiencing hot flashes. ( Brown, JN; Wright, BR, 2009)
"Forty patients who were breast cancer survivors and were suffering from hot flushes to the degree that they seeked for treatment were included in the study and randomly divided into two groups: group I: (N = 20) stellate ganglion block was done for the patients of this group; and group II: (N = 20) in this group, the patients received 75 mg pregabalin twice daily."5.19Management of hot flushes in breast cancer survivors: comparison between stellate ganglion block and pregabalin. ( Othman, AH; Zaky, AH, 2014)
" This prospective randomized double-blind study was conducted to evaluate the effects of gabapentin on intraoperative propofol requirements, hemodynamic variables, and postoperative pain relief in breast cancer patients."5.17Effect of gabapentin pretreatment on propofol consumption, hemodynamic variables, and postoperative pain relief in breast cancer surgery. ( Bala, I; Bharti, N; Narayan, V; Singh, G, 2013)
"Preoperative administration of gabapentin reduced intraoperative propofol requirements and postoperative analgesic consumption in breast cancer patients undergoing total mastectomy."5.17Effect of gabapentin pretreatment on propofol consumption, hemodynamic variables, and postoperative pain relief in breast cancer surgery. ( Bala, I; Bharti, N; Narayan, V; Singh, G, 2013)
"Gabapentin is used for the treatment of hot flashes and neuropathic pain in breast cancer survivors, and is commonly used off-label for the treatment of anxiety."5.16A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors. ( Amos, E; Heckler, C; Jacobs, A; Kirshner, JJ; Lavigne, JE; Lord, R; Mathews, JL; Morrow, GR; Mustian, K; Palesh, O, 2012)
"To assess the efficacy and the tolerability of gabapentin 900 mg/day compared to vitamin E for the control of vasomotor symptoms in 115 women with breast cancer."5.14Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E. ( Biglia, N; Bounous, V; Marenco, D; Moggio, G; Peano, E; Ponzone, R; Sgandurra, P; Sismondi, P; Tomasi Cont, N, 2009)
"Breast cancer survivors prefer venlafaxine over gabapentin for treating hot flashes."5.14Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. ( Bordeleau, L; Ennis, M; Goodwin, PJ; Haq, R; Jugovic, O; Loprinzi, CL; Pritchard, KI; Warr, D, 2010)
"In this pilot study, 22 women with breast cancer on tamoxifen therapy with at least two hot flashes a day took oral gabapentin at 300 mg three times a day for 4 weeks."5.11Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer. ( Griggs, JJ; Guttuso, TJ; Morrow, GR; Pandya, KJ; Roscoe, JA; Rosenblatt, JD; Sahasrabudhe, DM; Thummala, AR, 2004)
" Fifty patients scheduled for breast cancer surgery were blindly randomized to receive gabapentin, eutectic mixture of local anesthetics cream, and ropivacaine in the wound or three placebos."5.11Multimodal analgesia with gabapentin and local anesthetics prevents acute and chronic pain after breast surgery for cancer. ( Fassoulaki, A; Melemeni, A; Sarantopoulos, C; Triga, A, 2005)
"In an anecdotal report, complete resolution of chemotherapy-induced nausea was seen in a patient with breast cancer, after she was placed on the anticonvulsant gabapentin."5.10Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. ( Griggs, J; Guttuso, T; Roscoe, J, 2003)
"Preoperative use of gabapentin was able to reduce acute and chronic postoperative pain, total morphine consumption and the occurrence of nausea following breast cancer surgery."4.98The efficacy of gabapentin in reducing pain intensity and morphine consumption after breast cancer surgery: A meta-analysis. ( Huang, Q; Jiang, Y; Li, J; Lin, H; Rong, Z; Wang, T; Xiong, J; Zhang, Q; Zhang, S, 2018)
" RCTs comparing gabapentin with placebo in patients undergoing breast cancer surgery were retrieved."4.98The efficacy of gabapentin in reducing pain intensity and morphine consumption after breast cancer surgery: A meta-analysis. ( Huang, Q; Jiang, Y; Li, J; Lin, H; Rong, Z; Wang, T; Xiong, J; Zhang, Q; Zhang, S, 2018)
"The purpose of this meta-analysis from randomized controlled trials (RCTs) was to determine the efficacy and safety of the preoperative use of gabapentin for the treatment of acute and chronic postoperative pain following breast cancer surgery."4.98The efficacy of gabapentin in reducing pain intensity and morphine consumption after breast cancer surgery: A meta-analysis. ( Huang, Q; Jiang, Y; Li, J; Lin, H; Rong, Z; Wang, T; Xiong, J; Zhang, Q; Zhang, S, 2018)
" Meanwhile, oral gabapentin was associated with a reduction of the total morphine consumption after breast cancer surgery."4.98The efficacy of gabapentin in reducing pain intensity and morphine consumption after breast cancer surgery: A meta-analysis. ( Huang, Q; Jiang, Y; Li, J; Lin, H; Rong, Z; Wang, T; Xiong, J; Zhang, Q; Zhang, S, 2018)
"Gabapentin and pregabalin administered perioperatively in patients undergoing breast cancer surgery improve acute postoperative pain as indicated by the reduction in opioid consumption."4.95Preoperative pregabalin or gabapentin for acute and chronic postoperative pain among patients undergoing breast cancer surgery: A systematic review and meta-analysis of randomized controlled trials. ( Busse, JW; Choi, S; Clarke, H; Devereaux, PJ; Dhaliwal, J; Khan, JS; Rai, AS, 2017)
" We included studies enrolling adult patients undergoing breast cancer surgery who were randomly assigned to preoperative gabapentin or pregabalin versus placebo or active control and assessed acute (≤24 h) or chronic (≥2 months) pain."4.95Preoperative pregabalin or gabapentin for acute and chronic postoperative pain among patients undergoing breast cancer surgery: A systematic review and meta-analysis of randomized controlled trials. ( Busse, JW; Choi, S; Clarke, H; Devereaux, PJ; Dhaliwal, J; Khan, JS; Rai, AS, 2017)
"Clonidine, SSRIs and SNRIs, gabapentin and relaxation therapy showed a mild to moderate effect on reducing hot flushes in women with a history of breast cancer."4.86Non-hormonal interventions for hot flushes in women with a history of breast cancer. ( Capurro, D; Corbalán, J; Letelier, LM; Moreno, G; Pantoja, T; Rada, G; Vera, C, 2010)
"Centrally active agents (eg, venlafaxine, paroxetine, gabapentin) are regarded as the most promising nonhormonal treatments for hot flashes in breast cancer survivors."4.84Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review. ( Bordeleau, L; Goodwin, P; Loprinzi, C; Pritchard, K, 2007)
"In this case, a two-month trial of gabapentin 600 mg/day failed to demonstrate efficacy in reducing the severity, frequency, and duration of hot flashes."3.81Treating recurrent postmenopausal vasomotor symptoms in a patient with a positive family history for breast cancer. ( Lake, J; Leong, C, 2015)
"To report a case of recurrent hot flashes unresponsive to gabapentin in a postmenopausal patient with a positive family history of breast cancer."3.81Treating recurrent postmenopausal vasomotor symptoms in a patient with a positive family history for breast cancer. ( Lake, J; Leong, C, 2015)
"A new study published in the Journal of Clinical Oncology has ascertained the efficacy of selective serotonin-reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors and gabapentin to decrease menopausal hot flashes."3.76Therapy: nonhormonal treatment of hot flashes-a viable alternative? ( Nachtigall, LE, 2010)
"116 consecutive patients scheduled for breast cancer surgery were prospectively scored according to pain, PONV and sedation after being introduced to a combined evidence-based, empiric multimodal opioid-sparing prevention and treatment regime consisting of Paracetamol, Celecoxib, Dextromethorphan, Gabapetin, Dexamethason and Ondansetron."3.74[Multimodal treatment of pain and nausea in breast cancer surgery]. ( Callesen, T; Gärtner, R; Kehlet, H; Kroman, N, 2008)
" We present a case of asterixis as a cause of falls and near falls in a patient with metastatic breast cancer and normal mental status who was receiving gabapentin."3.73Asterixis related to gabapentin as a cause of falls. ( Babiy, M; Hand, M; Herklotz, M; Stubblefield, MD, 2005)
" Our results show that met-enkephalin, substance P, bombesin, dopamine, and norepinephrine have a stimulatory effect on the migration of the breast cancer cells; moreover, these cells show positive chemotaxis towards norepinephrine as was analyzed by the directionality and persistence on a single-cell basis."3.72Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. ( Drell, TL; Entschladen, F; Joseph, J; Lang, K; Niggemann, B; Zaenker, KS, 2003)
"Hot flashes are a common and debilitating symptom among survivors of breast cancer."2.80Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial. ( Bowman, MA; Bruner, D; DeMichele, A; Farrar, JT; Mao, JJ; Xie, SX, 2015)
"Forty patients who were breast cancer survivors and were suffering from hot flushes to the degree that they seeked for treatment were included in the study and randomly divided into two groups: group I: (N = 20) stellate ganglion block was done for the patients of this group; and group II: (N = 20) in this group, the patients received 75 mg pregabalin twice daily."2.79Management of hot flushes in breast cancer survivors: comparison between stellate ganglion block and pregabalin. ( Othman, AH; Zaky, AH, 2014)
"Women who have survived breast cancer have hot flushes that are "significantly more frequent, severe, distressing, and of greater duration" than in other women."2.79Management of hot flushes in breast cancer survivors: comparison between stellate ganglion block and pregabalin. ( Othman, AH; Zaky, AH, 2014)
"Gabapentin is an inhibitory neurotransmitter of the central nervous system."2.78Effect of gabapentin pretreatment on propofol consumption, hemodynamic variables, and postoperative pain relief in breast cancer surgery. ( Bala, I; Bharti, N; Narayan, V; Singh, G, 2013)
"Subjects were 420 breast cancer patients who had completed all chemotherapy cycles."2.77A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors. ( Amos, E; Heckler, C; Jacobs, A; Kirshner, JJ; Lavigne, JE; Lord, R; Mathews, JL; Morrow, GR; Mustian, K; Palesh, O, 2012)
"Of 200 consecutive breast cancer patients, 191 received the full package."2.75Multimodal prevention of pain, nausea and vomiting after breast cancer surgery. ( Callesen, T; Gärtner, R; Kehlet, H; Kroman, N, 2010)
"Gabapentin was also particularly effective in improving the quality of sleep (PSQI score reduction: 21."2.74Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E. ( Biglia, N; Bounous, V; Marenco, D; Moggio, G; Peano, E; Ponzone, R; Sgandurra, P; Sismondi, P; Tomasi Cont, N, 2009)
"Gabapentin is a promising new agent in the treatment of tamoxifen induced hot flashes, and should be studied further."2.71Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer. ( Griggs, JJ; Guttuso, TJ; Morrow, GR; Pandya, KJ; Roscoe, JA; Rosenblatt, JD; Sahasrabudhe, DM; Thummala, AR, 2004)
"In this pilot study, 22 women with breast cancer on tamoxifen therapy with at least two hot flashes a day took oral gabapentin at 300 mg three times a day for 4 weeks."2.71Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer. ( Griggs, JJ; Guttuso, TJ; Morrow, GR; Pandya, KJ; Roscoe, JA; Rosenblatt, JD; Sahasrabudhe, DM; Thummala, AR, 2004)
"Fifty patients scheduled for breast cancer surgery were blindly randomized to receive gabapentin, eutectic mixture of local anesthetics cream, and ropivacaine in the wound or three placebos."2.71Multimodal analgesia with gabapentin and local anesthetics prevents acute and chronic pain after breast surgery for cancer. ( Fassoulaki, A; Melemeni, A; Sarantopoulos, C; Triga, A, 2005)
"The secondary outcomes were incidence of chronic pain and complications (the incidence of nausea)."2.58The efficacy of gabapentin in reducing pain intensity and morphine consumption after breast cancer surgery: A meta-analysis. ( Huang, Q; Jiang, Y; Li, J; Lin, H; Rong, Z; Wang, T; Xiong, J; Zhang, Q; Zhang, S, 2018)
"We searched the Cochrane Breast Cancer Group Specialised Register, CENTRAL (The Cochrane Library), MEDLINE, EMBASE, LILACS, CINAHL, PsycINFO (August 2008) and WHO ICTRP Search Portal."2.46Non-hormonal interventions for hot flushes in women with a history of breast cancer. ( Capurro, D; Corbalán, J; Letelier, LM; Moreno, G; Pantoja, T; Rada, G; Vera, C, 2010)
"Gabapentin is an anticonvulsant that the United States Food and Drug Administration approved as an adjunct therapy for partial seizures and postherpetic neuralgia."2.45Use of gabapentin in patients experiencing hot flashes. ( Brown, JN; Wright, BR, 2009)
"Women with breast cancer may experience treatment-induced menopausal symptoms or natural menopause."2.44Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review. ( Bordeleau, L; Goodwin, P; Loprinzi, C; Pritchard, K, 2007)
"Women treated for breast cancer and men receiving androgen ablation for prostate cancer experience hot flushes that are more frequent, severe and longer lasting than those experienced by the general menopausal population."2.43Treatment of hot flushes in breast and prostate cancer. ( Adelson, KB; Hershman, DL; Loprinzi, CL, 2005)
"In men with prostate cancer, hot flushes occur after surgical or medical castration."2.43Treatment of hot flushes in breast and prostate cancer. ( Adelson, KB; Hershman, DL; Loprinzi, CL, 2005)
"5 mg/d, are reasonable initial dosages, and if symptoms do not improve within a week or two, the dosage can be doubled."2.42Management of hot flashes in breast cancer survivors and men with prostate cancer. ( Stearns, V, 2004)
"The most effective nonhormonal treatments for hot flashes include agents from the selective serotonin or noradrenergic reuptake inhibitor (SSRI/SNRI) family."2.42Management of hot flashes in breast cancer survivors and men with prostate cancer. ( Stearns, V, 2004)
"Hot flashes are a significant complaint among many breast cancer survivors and many men undergoing androgen deprivation therapy for prostate cancer."2.42Management of hot flashes in breast cancer survivors and men with prostate cancer. ( Stearns, V, 2004)
"Menopausal symptoms following breast cancer can occur at an earlier age, be more severe and significantly influence a woman's overall wellbeing, in particular, sexual function, quality of life and adherence to treatment."1.48The Management of Menopausal Symptoms in Women Following Breast Cancer: An Overview. ( Baber, R; Phua, C, 2018)
"Women affected by breast cancer (BC) will often go through menopause at an earlier age and display more frequent and severe symptoms than women who have a natural menopause."1.40Treatment of climacteric symptoms in breast cancer patients: a retrospective study from a medication databank. ( Ameye, L; Antoine, C; Paesmans, M; Rozenberg, S, 2014)
"Baclofen-induced breast cancer metastasis was mediated by ERK1/2 pathway."1.40GABAergic signaling facilitates breast cancer metastasis by promoting ERK1/2-dependent phosphorylation. ( Li, J; Li, X; Ning, N; Wei, C; Yao, Z; Zhang, D, 2014)
"Bidirectional interplay of breast cancer cells and native brain cells in metastasis is poorly understood and rarely studied."1.40Human breast cancer metastases to the brain display GABAergic properties in the neural niche. ( Choy, C; Hambrecht, AC; Jandial, R; Kowolik, CM; Li, H; Neman, J; Roberts, E; Termini, J; Vaidehi, N; Wilczynski, S, 2014)
"Delirium is still one of the most common and distressing symptoms in palliative care patients."1.38Reversible delirium in an advanced cancer patient. ( Jagsch, C; Kierner, KA; Watzke, HH, 2012)
"A total of 578 women with breast cancer were managed at the Menopausal Symptoms After Cancer Clinic between January 2003 and December 2008."1.36The multidisciplinary management of menopausal symptoms after breast cancer: a unique model of care. ( Doherty, DA; Emery, LI; Gregson, J; Hickey, M; Saunders, CM, 2010)
"Menopausal symptom management after breast cancer may be complex, and we present a novel model of care using a multidisciplinary approach."1.36The multidisciplinary management of menopausal symptoms after breast cancer: a unique model of care. ( Doherty, DA; Emery, LI; Gregson, J; Hickey, M; Saunders, CM, 2010)
"116 consecutive patients scheduled for breast cancer surgery were prospectively scored according to pain, PONV and sedation after being introduced to a combined evidence-based, empiric multimodal opioid-sparing prevention and treatment regime consisting of Paracetamol, Celecoxib, Dextromethorphan, Gabapetin, Dexamethason and Ondansetron."1.35[Multimodal treatment of pain and nausea in breast cancer surgery]. ( Callesen, T; Gärtner, R; Kehlet, H; Kroman, N, 2008)
"Acquired generalized repetitive myoclonus may be mistaken for tremor."1.34Whole-body tremulousness: isolated generalized polymyoclonus. ( Ahlskog, JE; Bower, JH; Glass, GA; Josephs, KA; Lennon, VA; McKeon, A; Pittock, SJ, 2007)
"To describe isolated generalized polymyoclonus and the outcomes of etiologic evaluations at the time of diagnosis."1.34Whole-body tremulousness: isolated generalized polymyoclonus. ( Ahlskog, JE; Bower, JH; Glass, GA; Josephs, KA; Lennon, VA; McKeon, A; Pittock, SJ, 2007)
"Treatment of myoclonus and underlying causes."1.34Whole-body tremulousness: isolated generalized polymyoclonus. ( Ahlskog, JE; Bower, JH; Glass, GA; Josephs, KA; Lennon, VA; McKeon, A; Pittock, SJ, 2007)
"All the patients had repetitive myoclonus of all limbs, impairing gait in 14 patients."1.34Whole-body tremulousness: isolated generalized polymyoclonus. ( Ahlskog, JE; Bower, JH; Glass, GA; Josephs, KA; Lennon, VA; McKeon, A; Pittock, SJ, 2007)
"Distinguishing myoclonus has etiologic and therapeutic implications."1.34Whole-body tremulousness: isolated generalized polymyoclonus. ( Ahlskog, JE; Bower, JH; Glass, GA; Josephs, KA; Lennon, VA; McKeon, A; Pittock, SJ, 2007)
"Most patients suffering from breast carcinoma do not die due to the primary tumor but from the development of metastases."1.32Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. ( Drell, TL; Entschladen, F; Joseph, J; Lang, K; Niggemann, B; Zaenker, KS, 2003)

Research

Studies (57)

TimeframeStudies, this research(%)All Research%
pre-19901 (1.75)18.7374
1990's1 (1.75)18.2507
2000's19 (33.33)29.6817
2010's33 (57.89)24.3611
2020's3 (5.26)2.80

Authors

AuthorsStudies
Germain, AR1
Carmody, LC1
Nag, PP1
Morgan, B1
Verplank, L1
Fernandez, C1
Donckele, E1
Feng, Y1
Perez, JR1
Dandapani, S1
Palmer, M1
Lander, ES1
Gupta, PB1
Schreiber, SL1
Munoz, B1
Deshpande, K1
Martirosian, V1
Nakamura, BN1
Iyer, M1
Julian, A1
Eisenbarth, R1
Shao, L1
Attenello, F1
Neman, J2
Dahn, ML1
Walsh, HR1
Dean, CA1
Giacomantonio, MA1
Fernando, W1
Murphy, JP1
Walker, OL1
Wasson, MD1
Gujar, S1
Pinto, DM1
Marcato, P1
Dhanani, LY1
Totton, RR1
Jara-Quijada, E1
Pérez-Won, M1
Tabilo-Munizaga, G1
Lemus-Mondaca, R1
González-Cavieres, L1
Palma-Acevedo, A1
Herrera-Lavados, C1
Milovanovic, S1
Grzegorczyk, A1
Świątek, Ł1
Grzęda, A1
Dębczak, A1
Tyskiewicz, K1
Konkol, M1
Li, Y2
Chang, P1
Sankaran, S1
Jang, H1
Nie, Y1
Zeng, A1
Hussain, S1
Wu, JY1
Chen, X2
Shi, L2
Senapati, A1
Chetri, BK1
Mitra, S1
Shelke, RG1
Rangan, L1
Chauhan, AS1
Tiwari, M1
Indoliya, Y1
Mishra, SK1
Lavania, UC1
Chauhan, PS1
Chakrabarty, D1
Tripathi, RD1
Akaputra, R1
Hatta, M1
Massi, MN1
Djaharuddin, I1
Bukhari, A1
Aminuddin, A1
Santoso, A1
Natzir, R1
Bahar, B1
Fachri, M1
Farsida, F1
Fathimah, A1
Ubaidah, FM1
Sridiana, E1
Dwiyanti, R1
Syukri, A1
Junita, AR1
Febrianti, A1
Primaguna, MR1
Azhar, A1
Rajaure, YS1
Thapa, B1
Budhathoki, L1
Rana, SR1
Khadka, M1
Batchu, UR1
Surapaneni, JR1
Cheemalamarri, C1
Mandava, K1
Puvvada, N1
Shetty, PR1
Mv, S1
Ranjbarian, P1
Goudarzi, F1
Akya, A1
Heidarinia, H1
Farasat, A1
Rostamian, M1
Suri, K1
Rajput, N1
Sharma, P1
Omble, AD1
Kulkarni, K1
Gahlay, GK1
Fernandez Garcia, E1
Paudel, U1
Noji, MC1
Bowman, CE1
Rustgi, AK1
Pitarresi, JR1
Wellen, KE1
Arany, Z1
Weissenrieder, JS1
Foskett, JK1
Lee, MS1
Han, HJ1
Choi, TI1
Lee, KH1
Baasankhuu, A1
Kim, HT1
Kim, CH1
Redd, PS1
Payero, L1
Gilbert, DM1
Page, CA1
King, R1
McAssey, EV1
Bodie, D1
Diaz, S1
Hancock, CN1
Lee, HS1
Jung, S1
Lee, SW1
Kim, YT1
Lee, J1
Ren, T1
Yu, Z1
Yu, H1
Deng, K1
Wang, Z1
Li, X2
Wang, H1
Wang, L2
Xu, Y1
Lascano, J1
Riley, L1
Khodayari, N1
Brantly, M1
Gupta, R1
Pradhan, J1
Haldar, A1
Murapaka, C1
Chandra Mondal, P1
Gao, R1
Dai, TY1
Meng, Z1
Sun, XF1
Liu, DX1
Shi, MM1
Li, HR1
Kang, X1
Bi, B1
Zhang, YT1
Xu, TW1
Yan, JM1
Jiang, Q1
Helmchen, G1
Guo, H2
Xiang, W1
Fang, Y1
Li, J6
Lin, Y1
An, X1
Jiang, D1
Cao, Q1
Xu, F1
Shiigi, H1
Wang, W1
Chen, Z1
Akosman, I1
Kumar, N1
Mortenson, R1
Lans, A1
De La Garza Ramos, R1
Eleswarapu, A1
Yassari, R1
Fourman, MS1
Jana, S1
Evans, EGB1
Jang, HS1
Zhang, S3
Zhang, H1
Rajca, A1
Gordon, SE1
Zagotta, WN1
Stoll, S1
Mehl, RA1
Miller, S1
Lee, DA1
Muhimpundu, S1
Maxwell, CA1
Liu, Z1
Shen, F1
Tong, Q1
Tang, M1
Peng, M1
Jiao, Z1
Jiang, Y2
Ao, L1
Fu, W1
Lv, X1
Jiang, G1
Hou, L1
Tu, WC1
McManamen, AM1
Su, X1
Jeacopello, I1
Takezawa, MG1
Hieber, DL1
Hassan, GW1
Lee, UN1
Anana, EV1
Locknane, MP1
Stephenson, MW1
Shinkawa, VAM1
Wald, ER1
DeMuri, GP1
Adams, KN1
Berthier, E1
Thongpang, S1
Theberge, AB1
Jiang, L1
Li, Z1
Dong, Q1
Rong, X1
Dong, G1
Huang, J1
Liang, Y1
Sun, S1
Zhang, R1
Miao, Z1
Senju, C1
Nakazawa, Y1
Oso, T1
Shimada, M1
Kato, K1
Matsuse, M1
Tsujimoto, M1
Masaki, T1
Miyazaki, Y1
Fukushima, S1
Tateishi, S1
Utani, A1
Murota, H1
Tanaka, K1
Mitsutake, N1
Moriwaki, S1
Nishigori, C1
Ogi, T1
Liu, C1
Zhang, X1
Wang, B1
Luo, Z1
Qian, D1
Liu, J1
Waterhouse, GIN1
Barbosa, M1
Marques-Sá, J1
Carvalho, C1
Fernandes, V1
Grilli, D1
Smetana, V1
Ahmed, SJ1
Shtender, V1
Pani, M1
Manfrinetti, P1
Mudring, AV1
Kuang, Y1
Yang, D1
Gai, S1
He, F1
An, B1
Yang, P1
Notini, L1
Schulz, K1
Kubeneck, LJ1
Grigg, ARC1
Rothwell, KA1
Fantappiè, G1
ThomasArrigo, LK1
Kretzschmar, R1
Siswanto, FM1
Okukawa, K1
Tamura, A1
Oguro, A1
Imaoka, S1
Kim, CG1
Jung, M1
Kim, HS1
Lee, CK1
Jeung, HC1
Koo, DH1
Bae, WK1
Zang, DY1
Kim, BJ1
Kim, H1
Yun, UJ1
Che, J1
Park, S1
Kim, TS1
Kwon, WS1
Park, J1
Cho, SW1
Nam, CM1
Chung, HC1
Rha, SY1
Colombo, N1
Van Gorp, T1
Matulonis, UA1
Oaknin, A1
Grisham, RN1
Fleming, GF1
Olawaiye, AB1
Nguyen, DD1
Greenstein, AE1
Custodio, JM1
Pashova, HI1
Tudor, IC1
Lorusso, D1
Zhou, F1
Jiang, Z1
Liang, H1
Ru, S1
Bettiol, AA1
Gao, W1
Lipsyc-Sharf, M1
Jain, E1
Collins, LC1
Rosenberg, SM1
Ruddy, KJ1
Tamimi, RM1
Schapira, L1
Come, SE1
Peppercorn, JM1
Borges, VF1
Warner, E1
Snow, C1
Krop, IE1
Kim, D1
Weiss, J1
Zanudo, JGT1
Partridge, AH1
Wagle, N1
Waks, AG1
Moskowitz, A1
Berg, KM1
Grossestreuer, AV1
Balaji, L1
Liu, X1
Cocchi, MN1
Chase, M1
Gong, MN1
Gong, J1
Parikh, SM1
Ngo, L1
Berlin, N1
Donnino, MW1
Zhou, Y1
Chen, Q1
Zhong, S1
Liu, H1
Koh, K1
Chen, H1
He, J1
Chen, J1
Liu, S1
Lin, L1
Zhang, Y1
Xiao, S1
Cao, S1
Yan, B2
Deng, J1
Gu, J1
Tao, Y1
Huang, C1
Lai, C1
Yong, Q1
Shen, Y1
Gong, Z1
Cao, J1
Mao, W1
Yao, Y1
Zhao, J1
Li, Q2
Liu, K1
Liu, B1
Feng, S1
Chandran, V1
Kunjan, C1
Veerapandian, V1
Kannan, R1
Zhang, T1
von Gunten, U1
Caruso, FR1
Goulart, CDL1
Jr, JCB1
de Oliveira, CR1
Mendes, RG1
Arena, R1
Borghi-Silva, A1
Carrasco-Nuñes, N1
Romano, M1
Cabeza, M1
Jiang, B1
Chen, D1
Zhao, C1
Ma, Y1
Yang, W1
Shen, X1
Satheeshkumar, K1
Saravanakumar, P1
Kalavathi, A1
Vennila, KN1
Elango, KP1
Mues Genannt Koers, L1
Prevost, D1
Paulssen, E1
Hoehr, C1
Ulhassan, Z1
Yang, S1
He, D1
Khan, AR1
Salam, A1
Azhar, W1
Muhammad, S1
Ali, S1
Hamid, Y1
Khan, I1
Sheteiwy, MS1
Zhou, W1
Wang, X1
Xie, Q1
Wang, Y1
Lü, H1
Fu, M1
Wang, D1
Woyka, J1
Cobin, RH1
Goodman, NF1
Rai, AS1
Khan, JS1
Dhaliwal, J1
Busse, JW1
Choi, S1
Devereaux, PJ1
Clarke, H1
Brzozowska, A1
Burdan, F1
Duma, D1
Solski, J1
Mazurkiewicz, M4
Phua, C1
Baber, R1
Lin, H1
Huang, Q1
Wang, T1
Zhang, Q1
Rong, Z1
Xiong, J1
Kanbayashi, Y1
Hosokawa, T1
Kitawaki, J1
Taguchi, T1
Bharti, N1
Bala, I1
Narayan, V1
Singh, G1
Lin, JN1
Lin, HY1
Yang, NS1
Li, YH1
Lee, MR1
Chuang, CH1
Ho, CT1
Kuo, SC1
Way, TD1
Hathaway, H1
Royce, ME1
Prossnitz, ER1
Miao, Y1
Koyuncu, T1
Oğuz, G1
Akben, S1
Nas, S1
Ünver, S1
Termini, J1
Wilczynski, S1
Vaidehi, N1
Choy, C1
Kowolik, CM1
Li, H1
Hambrecht, AC1
Roberts, E1
Jandial, R1
Othman, AH1
Zaky, AH1
Zhang, D1
Yao, Z1
Wei, C1
Ning, N1
Antoine, C1
Ameye, L1
Paesmans, M1
Rozenberg, S1
Merriman, JD1
Aouizerat, BE1
Cataldo, JK1
Dunn, LB1
Kober, K1
Langford, DJ1
West, C1
Cooper, BA1
Paul, SM1
Miaskowski, C1
Leong, C1
Lake, J1
Van Swearingen, AE1
Siegel, MB1
Anders, CK1
Mao, JJ2
Bowman, MA1
Xie, SX2
Bruner, D1
DeMichele, A1
Farrar, JT1
Garland, SN1
Seluzicki, C1
Basal, C1
Gärtner, R3
Callesen, T3
Kroman, N3
Kehlet, H4
Evoli, A1
Brown, JN1
Wright, BR1
Biglia, N1
Sgandurra, P1
Peano, E1
Marenco, D1
Moggio, G1
Bounous, V1
Tomasi Cont, N1
Ponzone, R1
Sismondi, P1
Kontos, M1
Agbaje, OF1
Rymer, J1
Fentiman, IS1
Nachtigall, LE1
Thümen, A1
Moser, A1
Amr, YM1
Yousef, AA1
Hickey, M1
Emery, LI1
Gregson, J1
Doherty, DA1
Saunders, CM1
Rada, G1
Capurro, D1
Pantoja, T1
Corbalán, J1
Moreno, G1
Letelier, LM1
Vera, C1
Bordeleau, L2
Pritchard, KI1
Loprinzi, CL2
Ennis, M1
Jugovic, O1
Warr, D1
Haq, R1
Goodwin, PJ1
Kierner, KA1
Jagsch, C1
Watzke, HH1
Lavigne, JE1
Heckler, C1
Mathews, JL1
Palesh, O1
Kirshner, JJ1
Lord, R1
Jacobs, A1
Amos, E1
Morrow, GR2
Mustian, K1
Sarkissian, A1
Neher, JO1
Singh, R1
St Anna, L1
Lefkowits, CC1
Arnold, RM1
Fassoulaki, A2
Patris, K1
Sarantopoulos, C2
Hogan, Q1
Guttuso, T1
Roscoe, J1
Griggs, J1
Drell, TL1
Joseph, J1
Lang, K1
Niggemann, B1
Zaenker, KS1
Entschladen, F1
Szczaurska, K1
Opolski, A3
Pandya, KJ1
Thummala, AR1
Griggs, JJ1
Rosenblatt, JD1
Sahasrabudhe, DM1
Guttuso, TJ1
Roscoe, JA1
Stearns, V1
Hsu, C1
Sliwa, JA1
Babiy, M1
Stubblefield, MD1
Herklotz, M1
Hand, M1
Adelson, KB1
Hershman, DL1
Triga, A1
Melemeni, A1
Pritchard, K1
Goodwin, P1
Loprinzi, C1
McKeon, A1
Pittock, SJ1
Glass, GA1
Josephs, KA1
Bower, JH1
Lennon, VA1
Ahlskog, JE1
Wietrzyk, J2
Radzikowski, C2
Kleinrok, Z2
Lamberts, SW1
Klijn, JG1
Birkenhäger, JC1

Clinical Trials (12)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effects of Connective Tissue Manipulation on Menopausal Symptoms[NCT05293860]58 participants (Anticipated)Interventional2022-04-04Recruiting
"Preoperative Gabapentin and Its Effects on Postoperative Analgesia in Patients Undergoing Cosmetic Breast Surgery"[NCT05997355]100 participants (Anticipated)Interventional2023-09-01Not yet recruiting
Gabapentin Regimens and Their Effects on Opioid Consumption[NCT03334903]Phase 477 participants (Actual)Interventional2018-05-15Completed
Early Acupuncture Treatment of Vasomotor Symptoms and Sleep Disorders in Breast Cancer Luteinising Hormone-releasing Hormone Analogues(LHRHa) Induced Menopause: AcuHOTFLASH Study[NCT05760222]90 participants (Anticipated)Interventional2021-11-25Recruiting
Self-acupressure for Cancer-related Symptom Cluster of Insomnia, Depression, and Anxiety in Cancer Patients: a Feasibility Randomized Controlled Trial[NCT03823456]114 participants (Anticipated)Interventional2018-12-04Recruiting
Acupuncture and Gabapentin for Hot Flashes Among Breast Cancer Survivors[NCT01005108]Phase 2120 participants (Actual)Interventional2009-01-31Completed
The Effect of Lidocaine to Prevent the Development of Chronic Post-Surgical Pain[NCT01619852]148 participants (Actual)Interventional2012-06-30Completed
Combined General Anesthesia Plus Paravertebral Block Versus General Anesthesia Plus Opioid Analgesia for Breast Cancer Surgery: A Prospective Randomized Trial[NCT01904266]60 participants (Actual)Interventional2013-05-31Completed
Multimodal Pain Treatment for Breast Cancer Surgery - a Prospective Cohort Study[NCT04875559]236 participants (Actual)Observational [Patient Registry]2021-04-19Completed
Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy: a Prospective, Randomized Study.[NCT00954187]8 participants (Actual)Interventional2009-11-30Terminated (stopped due to PI left institution)
Comparative Evaluation of Osteopathy Treatment Efficacy in Pain Support After Breast Surgery in Oncology[NCT01403168]28 participants (Actual)Interventional2011-04-30Terminated (stopped due to Recruitment difficulties)
Comparison of Hypnotherapy Versus Gabapentin in the Treatment of Hot Flashes in Breast Cancer Survivors or Women at Risk of Developing Breast Cancer.[NCT00711529]Phase 327 participants (Actual)Interventional2008-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

"VAS Score 1: How Much Pain do You Feel in Your Operative Site When Resting?"

Surgical site pain. Scale 0-10, with 0 best and 10 worst (NCT03334903)
Timeframe: 2-3 months after surgery (at 2nd postoperative appointment)

Interventionscore on 10-point scale (Mean)
Standard of Care2.26
Postoperative Gabapentin Regimen2.46

"VAS Score 2: How Much Pain do You Feel in Your Operative Site When Moving?"

Surgical site pain. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

Interventionscore on a 10-point scale (Mean)
Standard of Care3.84
Postoperative Gabapentin Regimen3.54

"VAS Score 3: How Well Are You Sleeping?"

Sleep quality. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

Interventionscore on a 10-point scale (Mean)
Standard of Care5.73
Postoperative Gabapentin Regimen6.38

"VAS Score 4: How Bad is Your Nausea?"

Nausea. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

Interventionscore on a 10-point scale (Mean)
Standard of Care0.36
Postoperative Gabapentin Regimen0.17

"VAS Score 5: How Satisfied Are You With Your Pain Management?"

Satisfaction. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

Interventionscore on a 10-point scale (Mean)
Standard of Care7.83
Postoperative Gabapentin Regimen8.48

Days Taking Opioids

Number of days until patients are finished consuming opioid medications after discharge. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

Interventiondays (Mean)
Standard of Care14.8
Postoperative Gabapentin Regimen18.7

Opioid Consumption

Mean opioid consumption, measured in mg of morphine equivalents. (NCT03334903)
Timeframe: 2-3 months following surgery (total amount measured at second postoperative appointment; means assessed afterwards).

Interventionmorphine equivalents (Mean)
Standard of Care287.0
Postoperative Gabapentin Regimen281.1

Number of Participants With Chronic Persistent Pain 3 Months After Surgery as Determined by Character Severity (Yes/no).

The participants development of chronic persistent pain 3 months after surgery as determined by character severity (yes/no). (NCT01619852)
Timeframe: 3 months

Interventionparticipants (Number)
Group L2
.9% Normal Saline Placebo6

Opioid Consumption

The amount of opioid analgesics consumed was converted to an equivalent dose of intravenous morphine. (NCT01619852)
Timeframe: 24 hours

Interventionequivalent dose of intravenous morphine (Median)
Group L34
.9% Normal Saline Placebo39

Postoperative Pain

Postoperative pain within the first 24 hours. Area under the numeric rating scale for pain versus time curve during the first 24 hours after surgery (score * hr). Numeric rating scale for pain on a scale of 0-10 (0 is no pain and 10 is high pain) versus time curve during the first 24 hours ( score * hr). The pain scores were collected upon arrival to recovery area, 30 minutes, 1 hour and every 6 hours up to 24 hours following the procedure. Minimum score is 60, Maximum score is 170. A higher value indicates more pain. (NCT01619852)
Timeframe: 24 hours

Interventionscore on a scale (Median)
Group L116
.9% Normal Saline Placebo119

Quality of Recovery

Quality of recovery (QoR-40 instrument) is a 40-item questionnaire that provides a global score and sub-scores across five dimensions: patient support, comfort, emotions, physical independence, and pain. Score range: 40 to 200. A score of 40 demonstrates poor recovery and a maximum score of 200 represents good recovery. The higher the score the better recovery after surgery. (NCT01619852)
Timeframe: 24 hours post operative

Interventionunits on a scale (Median)
Lidocaine (Group L)158
.9% Normal Saline Placebo169

Post-surgical Persistent Pain Using Validated Questionnaires (S-LANNS Questionnaire, McGill Questionnaire, Brief Pain Inventory) to Assess Pain Qualities in Accordance With IMMPACT Recommendations.

The development of chronic pain 3 months after surgery determined by the Leads Assessment of Neuropathic Symptoms and Signs (LANSS) scale, a valid 7-item tool for identifying patients whose pain is dominated by neuropathic mechanisms. Each item is a binary response (yes or no) to the presence of symptoms (5 items) or clinical signs (2 items), range 0-24 points. A score ≥ 12, neuropathic mechanisms are likely to be contributing to the patient's pain. A score < 12 is unlikely to be contributing. McGill questionnaire (Sensory domain) - 11 descriptors rated on an intensity scale as 0=none, 1=mild, 2=moderate, 3=severe. The higher the score, greater the pain (range 0-33). McGill questionnaire (Motivational-affective) 4 affect descriptors rated on an intensity scale as 0=none, 1=mild, 2=moderate, 3=severe.The higher the score the greater the pain (range 0-12) Brief pain inventory - pain severity (0, no pain, 10 excruciating pain); Greater the score; greater the pain (range 0-10). (NCT01619852)
Timeframe: 3 months

,
Interventionunits on a scale (Median)
S-LANNSMcGill Questionaire-Sensory DiscrimationMcGill Questionaire-Motivational-affectiveBrief Pain Inventory
.9% Normal Saline Placebo3301
Group L3401

Hot Flash Related Daily Interference Score (HFRDIS)

The HFRDIS is a validated survey of 10 questions asking patients to rate ten hot flash-related symptoms on a scale of 0-10. The HFRDIS is a sum of the scores in each category, so that total score can range from 0 (no symptoms) to 100 (10 severe symptoms). These surveys were conducted at the time of enrollment (baseline), after four weeks of treatment, and at the conclusion of the study (8 weeks). All nine women who initiated hypnotherapy treatment completed the survey at the end of 8 weeks. One woman in the gabapentin arm did not submit a survey at 8 weeks. (NCT00711529)
Timeframe: Week 8

Interventionunits on a scale (HFRDIS) (Median)
Hypnotherapy26
Gabapentin22

Hot Flash Related Daily Interference Score (HFRDIS)

The HFRDIS is a validated survey of 10 questions asking patients to rate ten hot flash-related symptoms on a scale of 0-10. The HFRDIS is a sum of the scores in each category, so that total score can range from 0 (no symptoms) to 100 (10 severe symptoms). These surveys were conducted at the time of enrollment (baseline), after four weeks of treatment, and at the conclusion of the study (8 weeks). Of 11 eligible women in the hypnotherapy arm, 2 never initiated treatment, and 3 did not complete the survey at this time point. Of the 14 eligible women in the gabapentin arm, 3 never initiated treatment, and 3 dropped out of the study before the 4 week time point. (NCT00711529)
Timeframe: Week 4

Interventionunits on a scale (HFRDIS) (Median)
Hypnotherapy25.5
Gabapentin21.5

Hot Flash Related Daily Interference Score (HFRDIS)

The HFRDIS is a validated survey of 10 questions asking patients to rate ten symptoms on a scale of 0-10. The HFRDIS is a sum of the scores in each category, so that total score can range from 0 (no symptoms) to 100 (10 severe symptoms). These surveys were conducted at the time of enrollment (baseline), after four weeks of treatment, and at the conclusion of the study (8 weeks). All women who were randomized were included in the baseline analysis (with the exception of 2 women excluded from the hypnotherapy arm who were deemed ineligible after randomization). (NCT00711529)
Timeframe: Baseline

Interventionunits on a scale (HFRDIS) (Median)
Hypnotherapy58
Gabapentin45.5

Hot Flash Severity Score

The patients kept daily hot flash diaries, including the total number of hot flashes they characterized as mild, moderate,severe and very severe. Hot flash severity scores were calculated by assigning one point to each mild hot flash, two points for each moderate hot flash, three points for each severe hot flash and four points for each very severe hot flash. The hot flash severity score for a 24 hour period was the sum of these scores. The score was calculated for each day in the diary. For each subject, median scores were calculated for each week (7 day period) of participation. The median hot flash severity score for the first week was considered the baseline. The median hot flash severity score for the fourth week is considered the week 4 time point. The median hot flash severity score for the eighth week is considered the week 8 time point. The median result for the group was then calculated at each of the timepoints. (NCT00711529)
Timeframe: Baseline

Interventionunits on a scale (severity score) (Median)
Hypnotherapy10
Gabapentin7.5

Hot Flash Severity Score

The patients kept daily hot flash diaries, including the total number of hot flashes they characterized as mild, moderate,severe and very severe. Hot flash severity scores were calculated by assigning one point to each mild hot flash, two points for each moderate hot flash, three points for each severe hot flash and four points for each very severe hot flash. The hot flash severity score for a 24 hour period was the sum of these scores. The score was calculated for each day in the diary. For each subject, median scores were calculated for each week (7 day period) of participation. The median hot flash severity score for the first week was considered the baseline. The median hot flash severity score for the fourth week is considered the week 4 time point. The median hot flash severity score for the eighth week is considered the week 8 time point. The median result for the group was then calculated at each of the timepoints. (NCT00711529)
Timeframe: Week 4

Interventionunits on a scale (severity score) (Median)
Hypnotherapy6.5
Gabapentin4

Hot Flash Severity Score

The patients kept daily hot flash diaries, including the total number of hot flashes they characterized as mild, moderate,severe and very severe. Hot flash severity scores were calculated by assigning one point to each mild hot flash, two points for each moderate hot flash, three points for each severe hot flash and four points for each very severe hot flash. The hot flash severity score for a 24 hour period was the sum of these scores. The score was calculated for each day in the diary. For each subject, median scores were calculated for each week (7 day period) of participation. The median hot flash severity score for the first week was considered the baseline. The median hot flash severity score for the fourth week is considered the week 4 time point. The median hot flash severity score for the eighth week is considered the week 8 time point. The median result for the group was then calculated at each of the timepoints. (NCT00711529)
Timeframe: Week 8

Interventionunits on a scale (severity score) (Median)
Hypnotherapy1.5
Gabapentin5

Number of Daily Hot Flashes

"Patients kept daily diaries of their hot flashes. The absolute number of hot flashes in a 24 hour period is number of daily hot flashes. The median number was calculated for each week of data. The median number of daily hot flashes for the first week (7 days) of participation is used as baseline. The median number of daily hot flashes for the fourth week (over 7 day interval) is reported for the week four time point. The median number of daily hot flashes for the eighth week (over 7 day interval) is reported for the week eight time point (study completion). A total of 15 diaries were submitted (7 hypnotherapy, 8 gabapentin). One person in each arm stopped recording in her diary before the 4 week mark." (NCT00711529)
Timeframe: Week 4

Interventiondaily hot flashes (Median)
Hypnotherapy4
Gabapentin4

Number of Daily Hot Flashes

"Patients kept daily diaries of their hot flashes. The absolute number of hot flashes in a 24 hour period is number of daily hot flashes. The median number was calculated for each week of data. The median number of daily hot flashes for the first week (7 days) of participation is used as baseline. The median number of daily hot flashes for the fourth week (over 7 day interval) is reported for the week four time point. The median number of daily hot flashes for the eighth week (over 7 day interval) is reported for the week eight time point (study completion). Of the 13 women randomized to the hypnotherapy arm, 2 women were ineligible and therefore not included in analysis. Two women were unable to initiate treatment and did not submit diaries. An additional two women completed treatment but lost their diaries, leaving 7 diaries for analysis at baseline. Of the 14 randomized to receive gabapentin, 6 dropped out of the study and did not submit diaries." (NCT00711529)
Timeframe: Baseline

Interventiondaily hot flashes (Median)
Hypnotherapy5
Gabapentin4.5

Number of Daily Hot Flashes

"Patients kept daily diaries of their hot flashes. The absolute number of hot flashes in a 24 hour period is number of daily hot flashes. The median number was calculated for each week of data. The median number of daily hot flashes for the first week (7 days) of participation is used as baseline. The median number of daily hot flashes for the fourth week (over 7 day interval) is reported for the week four time point. The median number of daily hot flashes for the eighth week (over 7 day interval) is reported for the week eight time point (study completion). One woman in the hypnotherapy arm and 3 women in the gabapentin arm stopped keeping their diary before the 8 week mark." (NCT00711529)
Timeframe: Week 8

Interventiondaily hot flashes (Median)
Hypnotherapy1
Gabapentin3

Reviews

11 reviews available for gamma-aminobutyric acid and Breast Neoplasms

ArticleYear
Preoperative pregabalin or gabapentin for acute and chronic postoperative pain among patients undergoing breast cancer surgery: A systematic review and meta-analysis of randomized controlled trials.
    Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2017, Volume: 70, Issue:10

    Topics: Amines; Analgesics; Breast Neoplasms; Chronic Pain; Cyclohexanecarboxylic Acids; Female; Gabapentin;

2017
Preoperative pregabalin or gabapentin for acute and chronic postoperative pain among patients undergoing breast cancer surgery: A systematic review and meta-analysis of randomized controlled trials.
    Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2017, Volume: 70, Issue:10

    Topics: Amines; Analgesics; Breast Neoplasms; Chronic Pain; Cyclohexanecarboxylic Acids; Female; Gabapentin;

2017
Preoperative pregabalin or gabapentin for acute and chronic postoperative pain among patients undergoing breast cancer surgery: A systematic review and meta-analysis of randomized controlled trials.
    Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2017, Volume: 70, Issue:10

    Topics: Amines; Analgesics; Breast Neoplasms; Chronic Pain; Cyclohexanecarboxylic Acids; Female; Gabapentin;

2017
Preoperative pregabalin or gabapentin for acute and chronic postoperative pain among patients undergoing breast cancer surgery: A systematic review and meta-analysis of randomized controlled trials.
    Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2017, Volume: 70, Issue:10

    Topics: Amines; Analgesics; Breast Neoplasms; Chronic Pain; Cyclohexanecarboxylic Acids; Female; Gabapentin;

2017
The efficacy of gabapentin in reducing pain intensity and morphine consumption after breast cancer surgery: A meta-analysis.
    Medicine, 2018, Volume: 97, Issue:38

    Topics: Amines; Breast Neoplasms; Chronic Pain; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Amino

2018
Use of gabapentin in patients experiencing hot flashes.
    Pharmacotherapy, 2009, Volume: 29, Issue:1

    Topics: Amines; Breast Neoplasms; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Female; Gabapentin;

2009
What can be done about hot flushes after treatment for breast cancer?
    Climacteric : the journal of the International Menopause Society, 2010, Volume: 13, Issue:1

    Topics: Amines; Anesthetics, Local; Breast Neoplasms; Bupivacaine; Clonidine; Complementary Therapies; Cyclo

2010
Non-hormonal interventions for hot flushes in women with a history of breast cancer.
    The Cochrane database of systematic reviews, 2010, Sep-08, Issue:9

    Topics: Acupuncture Therapy; Amines; Breast Neoplasms; Clonidine; Cyclohexanecarboxylic Acids; Excitatory Am

2010
Clinical Inquiry: Do venlafaxine and gabapentin control hot flashes in women with a history of breast cancer?
    The Journal of family practice, 2012, Volume: 61, Issue:12

    Topics: Amines; Anti-Anxiety Agents; Breast Neoplasms; Constipation; Cyclohexanecarboxylic Acids; Cyclohexan

2012
[The role of GABA-ergic system in carcinogenesis].
    Postepy higieny i medycyny doswiadczalnej, 2003, Volume: 57, Issue:5

    Topics: Breast Neoplasms; Central Nervous System; Colonic Neoplasms; Digestive System Neoplasms; Female; gam

2003
Management of hot flashes in breast cancer survivors and men with prostate cancer.
    Current oncology reports, 2004, Volume: 6, Issue:4

    Topics: Amines; Anti-Anxiety Agents; Breast Neoplasms; Complementary Therapies; Contraceptives, Oral, Synthe

2004
Treatment of hot flushes in breast and prostate cancer.
    Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:7

    Topics: Amines; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cimicifuga; Contraindications; Cyclohexan

2005
Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review.
    Clinical therapeutics, 2007, Volume: 29, Issue:2

    Topics: Amines; Antidepressive Agents; Breast Neoplasms; Complementary Therapies; Cyclohexanecarboxylic Acid

2007
[Prolactin].
    Nederlands tijdschrift voor geneeskunde, 1978, Sep-09, Volume: 122, Issue:36

    Topics: Adenoma; Adult; Amenorrhea; Breast Neoplasms; Dopamine; Estrogens; Female; gamma-Aminobutyric Acid;

1978

Trials

15 trials available for gamma-aminobutyric acid and Breast Neoplasms

ArticleYear
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
    Sexuality research & social policy : journal of NSRC : SR & SP, 2023, Apr-05

    Topics: Acute Kidney Injury; Adult; Aged; Albumins; Alloys; Amides; Amino Acids; Animals; Antineoplastic Com

2023
Effect of gabapentin pretreatment on propofol consumption, hemodynamic variables, and postoperative pain relief in breast cancer surgery.
    Acta anaesthesiologica Taiwanica : official journal of the Taiwan Society of Anesthesiologists, 2013, Volume: 51, Issue:1

    Topics: Adult; Amines; Analgesics; Anesthetics, Intravenous; Breast Neoplasms; Cyclohexanecarboxylic Acids;

2013
[The effects of pregabaline on postoperative pain and opioid consumption used perioperatively in patients undergoing modified radical mastectomy].
    Agri : Agri (Algoloji) Dernegi'nin Yayin organidir = The journal of the Turkish Society of Algology, 2013, Volume: 25, Issue:4

    Topics: Adult; Analgesics; Analgesics, Opioid; Breast Neoplasms; Female; gamma-Aminobutyric Acid; Humans; In

2013
Management of hot flushes in breast cancer survivors: comparison between stellate ganglion block and pregabalin.
    Pain medicine (Malden, Mass.), 2014, Volume: 15, Issue:3

    Topics: Adult; Aged; Breast Neoplasms; Female; gamma-Aminobutyric Acid; Hot Flashes; Humans; Middle Aged; Pr

2014
Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Nov-01, Volume: 33, Issue:31

    Topics: Adult; Aged; Amines; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclohexanecarboxylic Acids; Electroa

2015
Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Nov-01, Volume: 33, Issue:31

    Topics: Adult; Aged; Amines; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclohexanecarboxylic Acids; Electroa

2015
Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Nov-01, Volume: 33, Issue:31

    Topics: Adult; Aged; Amines; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclohexanecarboxylic Acids; Electroa

2015
Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Nov-01, Volume: 33, Issue:31

    Topics: Adult; Aged; Amines; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclohexanecarboxylic Acids; Electroa

2015
Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Nov-01, Volume: 33, Issue:31

    Topics: Adult; Aged; Amines; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclohexanecarboxylic Acids; Electroa

2015
Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Nov-01, Volume: 33, Issue:31

    Topics: Adult; Aged; Amines; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclohexanecarboxylic Acids; Electroa

2015
Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Nov-01, Volume: 33, Issue:31

    Topics: Adult; Aged; Amines; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclohexanecarboxylic Acids; Electroa

2015
Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Nov-01, Volume: 33, Issue:31

    Topics: Adult; Aged; Amines; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclohexanecarboxylic Acids; Electroa

2015
Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Nov-01, Volume: 33, Issue:31

    Topics: Adult; Aged; Amines; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclohexanecarboxylic Acids; Electroa

2015
Comparative effectiveness of electro-acupuncture versus gabapentin for sleep disturbances in breast cancer survivors with hot flashes: a randomized trial.
    Menopause (New York, N.Y.), 2017, Volume: 24, Issue:5

    Topics: Acupuncture Therapy; Adult; Aged; Amines; Anti-Anxiety Agents; Breast Neoplasms; Cyclohexanecarboxyl

2017
Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E.
    Climacteric : the journal of the International Menopause Society, 2009, Volume: 12, Issue:4

    Topics: Adult; Aged; Amines; Breast Neoplasms; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminob

2009
Evaluation of efficacy of the perioperative administration of Venlafaxine or gabapentin on acute and chronic postmastectomy pain.
    The Clinical journal of pain, 2010, Volume: 26, Issue:5

    Topics: Acute Disease; Adult; Amines; Analgesics; Breast Neoplasms; Chronic Disease; Cyclohexanecarboxylic A

2010
Multimodal prevention of pain, nausea and vomiting after breast cancer surgery.
    Minerva anestesiologica, 2010, Volume: 76, Issue:10

    Topics: Acetaminophen; Aged; Amines; Analgesics, Non-Narcotic; Anesthesia Recovery Period; Anesthesia, Intra

2010
Multimodal prevention of pain, nausea and vomiting after breast cancer surgery.
    Minerva anestesiologica, 2010, Volume: 76, Issue:10

    Topics: Acetaminophen; Aged; Amines; Analgesics, Non-Narcotic; Anesthesia Recovery Period; Anesthesia, Intra

2010
Multimodal prevention of pain, nausea and vomiting after breast cancer surgery.
    Minerva anestesiologica, 2010, Volume: 76, Issue:10

    Topics: Acetaminophen; Aged; Amines; Analgesics, Non-Narcotic; Anesthesia Recovery Period; Anesthesia, Intra

2010
Multimodal prevention of pain, nausea and vomiting after breast cancer surgery.
    Minerva anestesiologica, 2010, Volume: 76, Issue:10

    Topics: Acetaminophen; Aged; Amines; Analgesics, Non-Narcotic; Anesthesia Recovery Period; Anesthesia, Intra

2010
Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Dec-10, Volume: 28, Issue:35

    Topics: Amines; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Breast Neoplasms; Cross-Over

2010
A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors.
    Breast cancer research and treatment, 2012, Volume: 136, Issue:2

    Topics: Amines; Anti-Anxiety Agents; Anxiety; Breast Neoplasms; Cyclohexanecarboxylic Acids; Female; Gabapen

2012
The analgesic effect of gabapentin and mexiletine after breast surgery for cancer.
    Anesthesia and analgesia, 2002, Volume: 95, Issue:4

    Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Antineoplastic Agents; Breast Neoplasms; Chr

2002
The analgesic effect of gabapentin and mexiletine after breast surgery for cancer.
    Anesthesia and analgesia, 2002, Volume: 95, Issue:4

    Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Antineoplastic Agents; Breast Neoplasms; Chr

2002
The analgesic effect of gabapentin and mexiletine after breast surgery for cancer.
    Anesthesia and analgesia, 2002, Volume: 95, Issue:4

    Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Antineoplastic Agents; Breast Neoplasms; Chr

2002
The analgesic effect of gabapentin and mexiletine after breast surgery for cancer.
    Anesthesia and analgesia, 2002, Volume: 95, Issue:4

    Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Antineoplastic Agents; Breast Neoplasms; Chr

2002
Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer.
    Lancet (London, England), 2003, May-17, Volume: 361, Issue:9370

    Topics: Acetates; Administration, Oral; Amines; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl

2003
Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer.
    Breast cancer research and treatment, 2004, Volume: 83, Issue:1

    Topics: Acetates; Administration, Oral; Amines; Breast Neoplasms; Cyclohexanecarboxylic Acids; Female; Gabap

2004
Multimodal analgesia with gabapentin and local anesthetics prevents acute and chronic pain after breast surgery for cancer.
    Anesthesia and analgesia, 2005, Volume: 101, Issue:5

    Topics: Acute Disease; Adult; Amines; Analgesia; Anesthetics, Local; Breast Neoplasms; Chronic Disease; Cycl

2005

Other Studies

31 other studies available for gamma-aminobutyric acid and Breast Neoplasms

ArticleYear
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
    Bioorganic & medicinal chemistry letters, 2013, Mar-15, Volume: 23, Issue:6

    Topics: Amides; Breast Neoplasms; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Humans; Neopla

2013
Neuronal exposure induces neurotransmitter signaling and synaptic mediators in tumors early in brain metastasis.
    Neuro-oncology, 2022, 06-01, Volume: 24, Issue:6

    Topics: Brain Neoplasms; Breast Neoplasms; Female; gamma-Aminobutyric Acid; Humans; Lung Neoplasms; Neurons;

2022
Metabolite profiling reveals a connection between aldehyde dehydrogenase 1A3 and GABA metabolism in breast cancer metastasis.
    Metabolomics : Official journal of the Metabolomic Society, 2022, 01-06, Volume: 18, Issue:1

    Topics: Aldehyde Dehydrogenase; Aldehyde Oxidoreductases; Animals; Breast Neoplasms; Cell Line, Tumor; Femal

2022
Consensus statement for non-hormonal-based treatments for menopausal symptoms.
    Post reproductive health, 2017, Volume: 23, Issue:2

    Topics: Amines; Anticonvulsants; Antihypertensive Agents; Behavior Therapy; Breast Neoplasms; Clonidine; Con

2017
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE.
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2017, Volume: 23, Issue:7

    Topics: Administration, Cutaneous; Administration, Oral; Aged; Amines; Breast Neoplasms; Cardiovascular Dise

2017
γ-amino butyric acid (GABA) level as an overall survival risk factor in breast cancer.
    Annals of agricultural and environmental medicine : AAEM, 2017, Sep-21, Volume: 24, Issue:3

    Topics: Adult; Aged; Breast Neoplasms; Cadherins; Cancer Survivors; Disease-Free Survival; Female; gamma-Ami

2017
The Management of Menopausal Symptoms in Women Following Breast Cancer: An Overview.
    Drugs & aging, 2018, Volume: 35, Issue:8

    Topics: Amines; Breast Neoplasms; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid;

2018
Statistical identification of predictors for paclitaxel-induced peripheral neuropathy in patients with breast or gynaecological cancer.
    Anticancer research, 2013, Volume: 33, Issue:3

    Topics: Aged; Analgesics, Opioid; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; gamma-Aminobu

2013
Chemical constituents and anticancer activity of yellow camellias against MDA-MB-231 human breast cancer cells.
    Journal of agricultural and food chemistry, 2013, Oct-09, Volume: 61, Issue:40

    Topics: Amino Acids; Antineoplastic Agents, Phytogenic; Antioxidants; Breast Neoplasms; Caffeine; Camellia;

2013
Influences of hydrocarbon linkers on the receptor binding affinities of gonadotropin-releasing hormone peptides.
    Bioorganic & medicinal chemistry letters, 2013, Oct-15, Volume: 23, Issue:20

    Topics: Aminocaproates; Animals; Breast Neoplasms; Caprylates; Cell Line, Tumor; Fatty Acids; Female; gamma-

2013
Human breast cancer metastases to the brain display GABAergic properties in the neural niche.
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Jan-21, Volume: 111, Issue:3

    Topics: 4-Aminobutyrate Transaminase; Brain Neoplasms; Breast Neoplasms; Cell Adhesion Molecules, Neuronal;

2014
GABAergic signaling facilitates breast cancer metastasis by promoting ERK1/2-dependent phosphorylation.
    Cancer letters, 2014, Jun-28, Volume: 348, Issue:1-2

    Topics: Animals; Breast Neoplasms; Cell Movement; Dose-Response Relationship, Drug; Female; GABA-B Receptor

2014
Treatment of climacteric symptoms in breast cancer patients: a retrospective study from a medication databank.
    Maturitas, 2014, Volume: 78, Issue:3

    Topics: Aged; Amines; Antidepressive Agents; Antineoplastic Agents; Aromatase Inhibitors; Belgium; Breast Ne

2014
Associations between catecholaminergic, GABAergic, and serotonergic genes and self-reported attentional function in oncology patients and their family caregivers.
    European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2015, Volume: 19, Issue:3

    Topics: Aged; Attention; Breast Neoplasms; California; Caregivers; Catecholamines; Cytokines; Family; Female

2015
Treating recurrent postmenopausal vasomotor symptoms in a patient with a positive family history for breast cancer.
    The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2015, Volume: 30, Issue:1

    Topics: Aged; Amines; Breast Neoplasms; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric

2015
Breast cancer brain metastases: evidence for neuronal-like adaptation in a 'breast-to-brain' transition?
    Breast cancer research : BCR, 2014, May-06, Volume: 16, Issue:3

    Topics: 4-Aminobutyrate Transaminase; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Female; GABA

2014
[Postoperative inconveniences after breast cancer surgery].
    Ugeskrift for laeger, 2008, Jun-02, Volume: 170, Issue:23

    Topics: Acetaminophen; Amines; Analgesics; Antiemetics; Antitussive Agents; Breast Neoplasms; Celecoxib; Cyc

2008
[Multimodal treatment of pain and nausea in breast cancer surgery].
    Ugeskrift for laeger, 2008, Jun-02, Volume: 170, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antiemetics; Antitussive Agents; Breast Neoplasm

2008
Antibody-phenotype correlation in stiff-person syndrome.
    Neurology, 2008, Dec-09, Volume: 71, Issue:24

    Topics: Autoantibodies; Biomarkers; Breast Neoplasms; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Huma

2008
Therapy: nonhormonal treatment of hot flashes-a viable alternative?
    Nature reviews. Endocrinology, 2010, Volume: 6, Issue:2

    Topics: Adrenergic Uptake Inhibitors; Amines; Antidepressive Agents; Breast Neoplasms; Contraindications; Cy

2010
An uncommon paraneoplastic Ri-positive opsoclonus-myoclonus-like syndrome and stiff-person syndrome with elevated glutamate/GABA ratio in the cerebrospinal fluid after breast cancer.
    Journal of neurology, 2010, Volume: 257, Issue:7

    Topics: Antigens, Neoplasm; Autoantibodies; Breast Neoplasms; Disease Progression; Female; gamma-Aminobutyri

2010
The multidisciplinary management of menopausal symptoms after breast cancer: a unique model of care.
    Menopause (New York, N.Y.), 2010, Volume: 17, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care Facilities; Amines; Anti-Anxiety Agents; Breast Neop

2010
Reversible delirium in an advanced cancer patient.
    Wiener medizinische Wochenschrift (1946), 2012, Volume: 162, Issue:1-2

    Topics: Amines; Analgesics; Analgesics, Opioid; Bone Neoplasms; Breast Neoplasms; Carcinoma, Intraductal, No

2012
Hot flashes in palliative care. Part 2 #262.
    Journal of palliative medicine, 2013, Volume: 16, Issue:1

    Topics: Amines; Analgesics; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clonidine; Cyclohexanecarboxy

2013
Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells.
    Breast cancer research and treatment, 2003, Volume: 80, Issue:1

    Topics: Antineoplastic Agents; Bombesin; Breast Neoplasms; Cell Migration Inhibition; Chemotaxis; Dopamine;

2003
Phantom breast pain as a source of functional loss.
    American journal of physical medicine & rehabilitation, 2004, Volume: 83, Issue:8

    Topics: Acetates; Activities of Daily Living; Amines; Anti-Anxiety Agents; Breast Neoplasms; Carcinoma in Si

2004
Asterixis related to gabapentin as a cause of falls.
    American journal of physical medicine & rehabilitation, 2005, Volume: 84, Issue:2

    Topics: Accidental Falls; Aged; Amines; Analgesics; Breast Neoplasms; Cyclohexanecarboxylic Acids; Diagnosis

2005
Perioperative analgesia to prevent chronic postmastectomy pain.
    Anesthesia and analgesia, 2006, Volume: 103, Issue:2

    Topics: Amines; Anesthetics, Local; Breast Neoplasms; Chronic Disease; Cyclohexanecarboxylic Acids; Female;

2006
Whole-body tremulousness: isolated generalized polymyoclonus.
    Archives of neurology, 2007, Volume: 64, Issue:9

    Topics: Adult; Aged; Amines; Anticonvulsants; Autoimmunity; Breast Neoplasms; Clonazepam; Cyclohexanecarboxy

2007
GABA level and GAD activity in human and mouse normal and neoplastic mammary gland.
    Journal of experimental & clinical cancer research : CR, 1999, Volume: 18, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Biomarkers, Tumor; Breast; Breast Neoplasms

1999
The role of GABA-ergic system in human mammary gland pathology and in growth of transplantable murine mammary cancer.
    Journal of experimental & clinical cancer research : CR, 2000, Volume: 19, Issue:3

    Topics: Adolescent; Adult; Animals; Baclofen; Biomarkers, Tumor; Breast Neoplasms; Female; GABA Agonists; ga

2000